PADI4 and rheumatoid arthritis: A phase I/II clinical trial (NCT03910543) is currently evaluating the safety and efficacy of the PAD4 inhibitor GSK3145095 in patients with rheumatoid arthritis, with NET formation as a secondary outcome measure.495